Plasma Level of Human Epididymis Protein 4 and Risk of Recurrence after First Venous Thromboembolism: The HUNT Study
Plasmaspiegel des humanen Epididymisproteins 4 und Rezidivrisiko nach erster venöser Thromboembolie: die HUNT-Studie
TH Open · 30.09.2026 · 10 (CP)
DOI: 10.1055/a-2961-2256 ↗Auf einen Blick
Bei 896 Personen mit erster VTE war HE4 im Plasma nicht mit einem höheren Rezidivrisiko verbunden. Auch in Subgruppen zeigte sich kein Zusammenhang.
Fragestellung
Sind Plasmaspiegel von humanem Epididymisprotein 4 (HE4) mit dem Risiko eines rezidivierenden VTE nach erster VTE assoziiert?
Methode
HUNT3-Kohorte (2006–2019) mit 896 Patient:innen nach erster VTE; HE4 im Plasma vor der VTE gemessen; Cox-Regressionen für Quartile, adjustiert für Alter, Geschlecht und BMI.
Ergebnisse
Im Follow-up entwickelten 116 Patient:innen eine rezidivierende VTE. Für Q4 vs. Q1 ergab sich HR 0,82 (95 %-KI 0,46–1,49); in Subgruppen kein signifikanter Zusammenhang.
Schlussfolgerung der Autor:innen
Die Autor:innen schlussfolgern, dass intrinsische HE4-Plasmaspiegel kein nützlicher Risikobiomarker für rezidivierende VTE sind.
Kernaussagen
- 116 Rezidive während des Follow-up
- Q4 vs. Q1: HR 0,82 (95 %-KI 0,46–1,49)
- Kein Zusammenhang in Subgruppenanalysen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift TH Open, erschienen am 30.09.2026. Verfasst von Celina J Cathro und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical MedicineThrombosis Research Group (TREC), UiT The Arctic University of NorwayTromsøTromsNorway. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Thrombosis Research Center.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Patients with incident venous thromboembolism (VTE) have a high risk of recurrence. Recent studies have shown that plasma levels of human epididymis protein 4 (HE4) are associated with increased risk of future incident VTE.
Objective
To investigate whether plasma HE4 levels are associated with risk of recurrent VTE.
Methods
Patients with first-lifetime VTE (n = 896) derived from the Trøndelag Health Study (HUNT3; 2006–2019) were followed from the VTE date. Symptomatic and objectively confirmed VTE recurrences were recorded during the study period. Plasma HE4 levels were measured by Somascan at the time of inclusion in the source cohort (HUNT3, prior to incident VTE). Cox regression models were used to estimate hazard ratios (HRs) for VTE recurrence across quartiles of plasma HE4 levels adjusted for age, sex, and body mass index. Subgroup analyses by type of incident VTE were also performed.
Results
During follow-up, 116 patients developed recurrent VTE. We found no significant association between quartiles of plasma HE4 levels and absolute or relative risk of recurrent VTE. The HR for recurrence in individuals with elevated plasma HE4 levels (Q4) versus low HE4 levels (Q1) was HR: 0.82 (95% confidence interval [CI]: 0.46–1.49). Similarly, no association was found between plasma HE4 levels and recurrent VTE in any subgroup analyses (index deep vein thrombosis, pulmonary embolism, provoked VTE, or unprovoked VTE).
Conclusion
Our results suggest that inherent plasma HE4 levels are not useful as a risk biomarker for recurrent VTE.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical MedicineThrombosis Research Group (TREC), UiT The Arctic University of NorwayTromsøTromsNorway.
- Division of Internal MedicineThrombosis Research Center (TREC), University Hospital of North NorwayTromsøTromsNorway.
- Department of Public Health and NursingHUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and TechnologyTrondheimTrøndelagNorway.
- HUNT Research Center, Norwegian University of Science and TechnologyTrondheimTrøndelagNorway.
- Department of ResearchSt Olav's Hospital HFTrondheimTrøndelagNorway.
ORCID-Profile: Sigrid K Brækkan
Förderung
- The Thrombosis Research Center
Zitieren
APA
Cathro, C. J., Brækkan, S. K., Hveem, K., & Hansen, J. B. (2026). Plasma Level of Human Epididymis Protein 4 and Risk of Recurrence after First Venous Thromboembolism: The HUNT Study. TH Open, 10(CP). https://doi.org/10.1055/a-2961-2256
Vancouver
Cathro CJ, Brækkan SK, Hveem K, Hansen JB. Plasma Level of Human Epididymis Protein 4 and Risk of Recurrence after First Venous Thromboembolism: The HUNT Study. TH Open. 2026;10(CP). doi:10.1055/a-2961-2256
BibTeX
@article{Cathro2026,
author = {Cathro, Celina J and Brækkan, Sigrid K and Hveem, Kristian and Hansen, John-Bjarne},
title = {Plasma Level of Human Epididymis Protein 4 and Risk of Recurrence after First Venous Thromboembolism: The HUNT Study},
journal = {TH Open},
year = {2026},
volume = {10},
number = {CP},
doi = {10.1055/a-2961-2256}
}
EUVIMED